Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000921895-25-000528
Filing Date
2025-02-18
Accepted
2025-02-18 17:48:57
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 30993
2 JOINT FILING AGREEMENT ex993to13d12927027_021825.htm EX-99.3 13560
  Complete submission text file 0000921895-25-000528.txt   46344
Mailing Address 100 SPY COURT MARKHAM A6 L3R 5H6
Business Address 100 SPY COURT MARKHAM A6 L3R 5H6 (905) 475-1234
Edesa Biotech, Inc. (Subject) CIK: 0001540159 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: SCHEDULE 13D | Act: 34 | File No.: 005-87615 | Film No.: 25636412
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 100 NORTH MAIN STREET SUITE 301 ALPHARETTA GA 30009
Business Address 100 NORTH MAIN STREET SUITE 301 ALPHARETTA GA 30009 646-844-0037
Velan Capital Investment Management LP (Filed by) CIK: 0001848809 (see all company filings)

EIN.: 844706623 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D